Desley van Zoggel

Improved outcomes for responders to induction chemotherapy 51 CHAPTER 3 References 1. Bosman SJ, Holman FA, Nieuwenhuijzen GAP, et al. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg. 2014;101:1280–1289. 2. Van Der Meij W, Rombouts AJM, Rutten H, et al. Treatment of Locally Recurrent Rectal Carcinoma in Previously (Chemo)Irradiated Patients: A Review. Dis Colon Rectum. 2016;59:148–156. 3. Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer. N Engl J Med. 2001;345:638–646. 4. NielsenMB, Laurberg S, HolmT. Current management of locally recurrent rectal cancer. Colorectal Disease. 2011;13:732–742. 5. Kusters M, Dresen RC, Martijn H, et al. Radicality of resection and survival after multimodality treatment is influenced by subsite of locally recurrent rectal cancer. Int J Radiat Oncol Biol Phys. 2009;75:1444–1449. 6. Westberg K, Palmer G, Hjern F, et al. Management and prognosis of locally recurrent rectal cancer – A national population-based study. Eur J Surg Oncol. 2018;44:100–107. 7. NielsenM, RasmussenP, PedersenB, et al. Early andLateOutcomes of Surgery for LocallyRecurrent Rectal Cancer: A Prospective 10-Year Study in the Total Mesorectal Excision Era. Ann Surg Oncol. 2015;22:2677–2684. 8. Valentini V, Morganti AG, Gambacorta MA, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006;64:1129–1139. 9. Dresen RC, Gosens MJ, Martijn H, et al. Radical Resection After IORT-Containing Multimodality Treatment is the Most Important Determinant for Outcome in Patients Treated for Locally Recurrent Rectal Cancer. Ann Surg Oncol. . Epub ahead of print 2008. DOI: 10.1245/s10434-0089896-z. 10. Alberda WJ, Verhoef C, Schipper MEI, et al. The Importance of a Minimal Tumor-Free Resection Margin in Locally Recurrent Rectal Cancer. Dis Colon Rectum. 2015;58:677–685. 11. Westberg K, Palmer G, Hjern F, et al. Population-based study of factors predicting treatment intention in patients with locally recurrent rectal cancer. Br J Surg. 2017;104:1866–1873. 12. Bhangu A, Beynon J, Brown G, et al. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. Br J Surg.;100 . Epub ahead of print 2013. DOI: 10.1002/BJS.9192_1. 13. Vermaas M, Ferenschild FTJ, Nuyttens JJME, et al. Preoperative radiotherapy improves outcome in recurrent rectal cancer. Dis Colon Rectum. 2005;48:918–928. 14. Wiig JN, LarsenSG, DuelandS, et al. Clinical outcome inpatientswith complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer. J Surg Oncol. 2005;92:70–75. 15. Yu SKT, Bhangu A, Tait DM, et al. Chemoradiotherapy response in recurrent rectal cancer. Cancer Med. 2014;3:111–117. 16. van Zoggel DMGI, Bosman SJ, Kusters M, et al. Preliminary results of a cohort study of induction chemotherapy-based treatment for locally recurrent rectal cancer. Br J Surg. 2018;105:447–452. 17. Mandard A -M, Dalibard F, Mandard J -C, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–2686.